Clinical Trials Browser

Phase 1 × INDUSTRY × navitoclax × Clear all

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Active not recruiting

21 enrolled

Myeloid

Neoplasms, Primary Myelofibrosis

NCT00788684 2025-02-20

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Phase 1 Completed

29 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Phase 1 Active not recruiting

85 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Terminated

1 enrolled

Myeloid

Neoplasms, Primary Myelofibrosis

NCT03181126 2021-10-14

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Phase 1 Completed

69 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00878449 2018-06-06

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Phase 1 Completed

12 enrolled

Other solid neoplasm

Solid Tumors

NCT00887757 2017-11-21

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

Phase 1 Completed

46 enrolled

Other solid neoplasm

Solid Tumors

NCT00891605 2017-11-21

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Phase 1 Completed

19 enrolled

Other solid neoplasm

Solid Tumors

NCT00982566 2017-11-21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Phase 1 Completed

37 enrolled

Other solid neoplasm

Lymphoid Malignancy

NCT01121133 2017-11-21

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Phase 1 Completed

12 enrolled

Lymphoid

Lymphoma

NCT01009073 2017-11-20

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Phase 1 Completed

51 enrolled

Other solid neoplasm

Solid Tumors

NCT00868413 2013-06-07

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Completed

32 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00888108 2012-05-22

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

Phase 1 Completed

41 enrolled

Other solid neoplasm

Solid Tumor

NCT01021358 2010-12-20

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Phase 1 Completed

12 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00743028 2010-10-07

Assess the Oral Bioavailability of New ABT-263 Formulations

Phase 1 Completed

36 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell